Cell-based Gene Therapy May Offer Long-term Treatment for Hemophilia A, Mouse Study Suggests
Industry News & Research
Cell therapy with endothelial progenitor cells and stem cells genetically engineered to produce a functional clotting factor VIII (FVIII) may provide a…
Advocacy Priorities Established by NHF
Advocacy & Legislation
The National Hemophilia Foundation (NHF) has advocated for the needs and interests of people affected by hemophilia and related bleeding disorders for…
GLHF Launches the 2019 Red Tie Campaign
GLHF News
It’s time to put on your red ties again and join us for the 2019 Red Tie Campaign! This March, during Bleeding…
uniQure Announces Updated Data from Phase 2B Dose Confirmation of AMT-061
Industry News & Research
uniQure is excited to announce that updated data from their Phase 2B dose-confirmation study of AMT-061, an investigational gene therapy for the…
Who Makes the Decision?
Living with a Bleeding Disorder
by: Derek L. Markley It has been more than eight years since St. Jude Children’s Research Hospital, University College London, and the…
What’s the Best Way to Learn About Your Bleeding Disorder?
Living with a Bleeding Disorder
by: Laurie Kelley Our world is biased toward visual information and learning, because humans are mainly visual beings. From advertising to teaching…
NHF and Partners Announce Innovative Infusion Logging Tool
Industry News & Research
The National Hemophilia Foundation (NHF) has announced a new two-year pilot program that aims to improve the efficacy of patient infusion logs…
Online Health Information: Is It Reliable?
Research
by: Paul Clement It’s an exciting time for people with inhibitors. In addition to bypassing agents, new products may prevent or control…
PT Study Focuses on Comprehensive Survey of Physical Activities Risks for 101 Activities
Industry News & Research
Physical therapists (PTs) at hemophilia treatment centers (HTCs) often consult with hemophilia patients about engaging in new physical activities like exercise, team/individual…
Catalyst Reports Positive Trial Updates for Subcutaneous Therapy for Hemophilia
Industry News & Research
Catalyst Biosciences, Inc recently reported updated interim data from their phase 2/3, multinational clinical study of marzeptacog alfa (MarzAA), a subcutaneous (administered…
GLHF Hosts Event to Help Young Adults Own Their Future
GLHF News
Part of GLHF’s mission is to educate the bleeding disorders community about opportunities and information that can benefit them and impact their…
Camp Klotty Pine Celebrates Five Successful Years of Service to the Bleeding Disorders Community
GLHF News
This past January, GLHF hosted more than 40 children, families, Hemophilia Treatment Center staff and donors to celebrate Camp Klotty Pine’s five…